Us Bancorp \De\ Arrowhead Pharmaceuticals, Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 34,522 shares of ARWR stock, worth $535,091. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,522

Previous 40,123 13.96%

Holding current value

$535,091

Previous $776,000 16.37%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	SELL	$17.7 - $26.34 $99,137 - $147,530	-5,601 Reduced 13.96%	34,522 $649,000
Q3 2024 Oct 28, 2024	SELL	$19.36 - $29.54 $96,548 - $147,315	-4,987 Reduced 11.06%	40,123 $776,000
Q2 2024 Aug 06, 2024	BUY	$21.87 - $28.24 $28,737 - $37,107	1,314 Added 3.0%	45,110 $1.17 Million
Q1 2024 May 07, 2024	SELL	$27.21 - $39.48 $65,548 - $95,107	-2,409 Reduced 5.21%	43,796 $1.25 Million
Q4 2023 Feb 09, 2024	SELL	$21.2 - $31.03 $20,118 - $29,447	-949 Reduced 2.01%	46,205 $1.41 Million
Q3 2023 Nov 03, 2023	BUY	$26.2 - $36.08 $31,964 - $44,017	1,220 Added 2.66%	47,154 $1.27 Million
Q2 2023 Aug 09, 2023	BUY	$25.16 - $41.38 $80,285 - $132,043	3,191 Added 7.47%	45,934 $1.64 Million
Q1 2023 May 09, 2023	BUY	$23.68 - $38.51 $586,814 - $954,316	24,781 Added 137.96%	42,743 $1.09 Million
Q4 2022 Feb 13, 2023	SELL	$28.0 - $40.56 $123,200 - $178,464	-4,400 Reduced 19.68%	17,962 $728,000
Q3 2022 Oct 27, 2022	BUY	$29.63 - $48.31 $186,431 - $303,966	6,292 Added 39.15%	22,362 $740,000
Q2 2022 Aug 01, 2022	SELL	$27.79 - $50.61 $37,460 - $68,222	-1,348 Reduced 7.74%	16,070 $566,000
Q1 2022 May 11, 2022	BUY	$39.62 - $69.97 $42,353 - $74,797	1,069 Added 6.54%	17,418 $801,000
Q4 2021 Feb 11, 2022	BUY	$58.09 - $82.51 $92,363 - $131,190	1,590 Added 10.77%	16,349 $1.08 Million
Q3 2021 Nov 10, 2021	BUY	$58.38 - $84.96 $66,553 - $96,854	1,140 Added 8.37%	14,759 $922,000
Q2 2021 Aug 05, 2021	BUY	$62.15 - $90.32 $63,641 - $92,487	1,024 Added 8.13%	13,619 $1.13 Million
Q1 2021 Apr 28, 2021	BUY	$61.35 - $90.47 $496,137 - $731,630	8,087 Added 179.39%	12,595 $836,000
Q4 2020 Feb 04, 2021	BUY	$43.82 - $85.37 $2,366 - $4,609	54 Added 1.21%	4,508 $346,000
Q3 2020 Nov 10, 2020	SELL	$33.21 - $51.27 $6,874 - $10,612	-207 Reduced 4.44%	4,454 $191,000
Q2 2020 Aug 07, 2020	SELL	$26.12 - $43.27 $4,701 - $7,788	-180 Reduced 3.72%	4,661 $201,000
Q1 2020 May 13, 2020	SELL	$20.56 - $63.12 $5,489 - $16,853	-267 Reduced 5.23%	4,841 $139,000
Q4 2019 Feb 04, 2020	BUY	$28.14 - $73.01 $7,822 - $20,296	278 Added 5.76%	5,108 $324,000
Q3 2019 Nov 08, 2019	BUY	$26.26 - $34.86 $5,829 - $7,738	222 Added 4.82%	4,830 $136,000
Q2 2019 Aug 13, 2019	BUY	$17.43 - $28.82 $2,126 - $3,516	122 Added 2.72%	4,608 $123,000
Q1 2019 May 08, 2019	SELL	$12.05 - $20.18 $3,193 - $5,347	-265 Reduced 5.58%	4,486 $82,000
Q4 2018 Feb 13, 2019	BUY	$10.74 - $19.7 $51,025 - $93,594	4,751 New	4,751 $59,000

Others Institutions Holding ARWR

# of Institutions

304

Shares Held

95.8M

Call Options Held

523K

Put Options Held

493K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.64B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account